CSI Market
Sign In | Register

Endra Life Sciences Inc (NDRA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NDRA Annual Cash Flow →
Tracking cash flow results across Endra Life Sciences Inc to Jun 30 2025 helps illustrate how Jun 30 2026's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-1.15
Depreciation & amortization0.02
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation1.12
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.08
Addition Warrants Issued During Exchange-
Finance Lease Right Of Use Asset Amortization-
Operating Lease Right Of Use Asset Amortization Expense0.03
Stock Payable For Investor Relations-
Fixed Assets Net Write Offs-
Property Plant And Equipment Net Write Offs-
Property Plant And Equipment Write Off-
Increase Decrease In Operating Lease Liability-0.03
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.03
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-0.52
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.61
Discontinued operations0.00
Net Cash flow from Operating Activities-2.05
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items2.69
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities2.67
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.36
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock3.80
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment For Settlement Of Notes-
Proceeds From Issuance Of Cashless Warrants-
Proceeds From Fundraising Activities-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.16
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow0.62
Total Cash Flow4.78
4 historic quarters locked

Sign in to unlock the full Endra Life Sciences Inc cash flow history.

Sign In Create Free Account

About Endra Life Sciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-090027

Figures are derived from filed reports and may be restated. Historical data is subject to revision.